274 related articles for article (PubMed ID: 16800786)
1. Immunomodulatory activities of IFN-gamma1b in combination with type I IFN: implications for the use of IFN-gamma1b in the treatment of chronic HCV infections.
Wang T; Blatt LM; Seiwert SD
J Interferon Cytokine Res; 2006 Jul; 26(7):473-83. PubMed ID: 16800786
[TBL] [Abstract][Full Text] [Related]
2. PEG-IFN alpha but not ribavirin alters NK cell phenotype and function in patients with chronic hepatitis C.
Markova AA; Mihm U; Schlaphoff V; Lunemann S; Filmann N; Bremer B; Berg T; Sarrazin C; Zeuzem S; Manns MP; Cornberg M; Herrmann E; Wedemeyer H
PLoS One; 2014; 9(4):e94512. PubMed ID: 24751903
[TBL] [Abstract][Full Text] [Related]
3. Distinct hepatitis C virus kinetics in HIV-infected patients treated with ribavirin plus either pegylated interferon alpha2a or alpha2b.
Vispo E; Barreiro P; Rodriguez-Nóvoa S; Morello J; Labarga P; Martín-Carbonero L; Maida I; García-Gascó P; Soriano V
Antivir Ther; 2008; 13(4):511-7. PubMed ID: 18672529
[TBL] [Abstract][Full Text] [Related]
4. Phase 2 study of the combination of merimepodib with peginterferon-alpha2b, and ribavirin in nonresponders to previous therapy for chronic hepatitis C.
Marcellin P; Horsmans Y; Nevens F; Grange JD; Bronowicki JP; Vetter D; Purdy S; Garg V; Bengtsson L; McNair L; Alam J
J Hepatol; 2007 Oct; 47(4):476-83. PubMed ID: 17629590
[TBL] [Abstract][Full Text] [Related]
5. Ribavirin downmodulates inducible costimulator on CD4+ T cells and their interleukin-10 secretion to assist in hepatitis C virus clearance.
Atsukawa M; Nakatsuka K; Kobayashi T; Shimizu M; Tamura H; Harimoto H; Takahashi H; Sakamoto C
J Gastroenterol Hepatol; 2012 Apr; 27(4):823-31. PubMed ID: 21871023
[TBL] [Abstract][Full Text] [Related]
6. [Immunology of HCV infection: the causes of impaired cellular immune response and the effect of antiviral treatment].
Pár G; Berki T; Pálinkás L; Balogh P; Szereday L; Halász M; Szekeres-Barthó J; Miseta A; Hegedus G; Mózsik G; Hunyady B; Pár A
Orv Hetil; 2006 Apr; 147(13):591-600. PubMed ID: 16623441
[TBL] [Abstract][Full Text] [Related]
7. Sequential immunological analysis of HBV/HCV co-infected patients during Peg-IFN/RBV therapy.
Kondo Y; Ueno Y; Ninomiya M; Tamai K; Tanaka Y; Inoue J; Kakazu E; Kobayashi K; Kimura O; Miura M; Yamamoto T; Kobayashi T; Igarashi T; Shimosegawa T
J Gastroenterol; 2012 Dec; 47(12):1323-35. PubMed ID: 22588246
[TBL] [Abstract][Full Text] [Related]
8. Ribavirin improves the IFN-γ response of natural killer cells to IFN-based therapy of hepatitis C virus infection.
Werner JM; Serti E; Chepa-Lotrea X; Stoltzfus J; Ahlenstiel G; Noureddin M; Feld JJ; Liang TJ; Rotman Y; Rehermann B
Hepatology; 2014 Oct; 60(4):1160-9. PubMed ID: 24700342
[TBL] [Abstract][Full Text] [Related]
9. Response of hepatitis C genotype-4 naïve patients to 24 weeks of Peg-interferon-alpha2b/ribavirin or induction-dose interferon-alpha2b/ribavirin/amantadine: a non-randomized controlled study.
El-Zayadi AR; Attia M; Barakat EM; Badran HM; Hamdy H; El-Tawil A; El-Nakeeb A; Selim O; Saied A
Am J Gastroenterol; 2005 Nov; 100(11):2447-52. PubMed ID: 16279899
[TBL] [Abstract][Full Text] [Related]
10. T helper type 1/T helper type 17-related cytokines in chronic hepatitis C patients before and after interferon and ribavirin therapy.
Fathy A; Ahmed AS; Metwally L; Hassan A
Med Princ Pract; 2011; 20(4):345-9. PubMed ID: 21576995
[TBL] [Abstract][Full Text] [Related]
11. Impaired ability of interferon-alpha-primed dendritic cells to stimulate Th1-type CD4 T-cell response in chronic hepatitis C virus infection.
Miyatake H; Kanto T; Inoue M; Sakakibara M; Kaimori A; Yakushijin T; Itose I; Miyazaki M; Kuzushita N; Hiramatsu N; Takehara T; Kasahara A; Hayashi N
J Viral Hepat; 2007 Jun; 14(6):404-12. PubMed ID: 17501761
[TBL] [Abstract][Full Text] [Related]
12. Interferon-gamma: biologic functions and HCV terapy (type I/II) (2 of 2 parts).
Gattoni A; Parlato A; Vangieri B; Bresciani M; Derna R
Clin Ter; 2006; 157(5):457-68. PubMed ID: 17147054
[TBL] [Abstract][Full Text] [Related]
13. 1(OH) vitamin D3 supplementation improves the sensitivity of the immune-response during Peg-IFN/RBV therapy in chronic hepatitis C patients-case controlled trial.
Kondo Y; Kato T; Kimura O; Iwata T; Ninomiya M; Kakazu E; Miura M; Akahane T; Miyazaki Y; Kobayashi T; Ishii M; Kisara N; Sasaki K; Nakayama H; Igarashi T; Obara N; Ueno Y; Morosawa T; Shimosegawa T
PLoS One; 2013; 8(5):e63672. PubMed ID: 23717463
[TBL] [Abstract][Full Text] [Related]
14. Rapid decrease in hepatitis C viremia by direct acting antivirals improves the natural killer cell response to IFNα.
Serti E; Park H; Keane M; O'Keefe AC; Rivera E; Liang TJ; Ghany M; Rehermann B
Gut; 2017 Apr; 66(4):724-735. PubMed ID: 26733671
[TBL] [Abstract][Full Text] [Related]
15. Predictive value of early virological response to treatment with different interferon-based regimens plus ribavirin in patients with chronic hepatitis C.
Napoli N; Giannelli G; Parisi CV; Antonaci A; Maddalena G; Antonaci S
New Microbiol; 2005 Jan; 28(1):13-21. PubMed ID: 15782622
[TBL] [Abstract][Full Text] [Related]
16. Cytoplasmic rods and rings autoantibodies developed during pegylated interferon and ribavirin therapy in patients with chronic hepatitis C.
Covini G; Carcamo WC; Bredi E; von Mühlen CA; Colombo M; Chan EK
Antivir Ther; 2012; 17(5):805-11. PubMed ID: 22293655
[TBL] [Abstract][Full Text] [Related]
17. 2'-,5'-Oligoadenylate synthetase response ratio predicting virological response to PEG-interferon-alpha2b plus ribavirin therapy in patients with chronic hepatitis C.
Kim KI; Kim SR; Sasase N; Taniguchi M; Harada S; Kinoshita K; Kim SH; Akimoto Y; Shikata M; Kimura N; Izawa S; Ohtani A; Nakao K; Motojima M; Kinoshita M; Hirai M; Ohzu M; Hirooka T; Nabeshima S; Ishii F; Tanaka K; Hotta H
J Clin Pharm Ther; 2006 Oct; 31(5):441-6. PubMed ID: 16958821
[TBL] [Abstract][Full Text] [Related]
18. Involvement of dendritic cell frequency and function in virological relapse in pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C patients.
Itose I; Kanto T; Inoue M; Miyazaki M; Miyatake H; Sakakibara M; Yakushijin T; Oze T; Hiramatsu N; Takehara T; Kasahara A; Katayama K; Kato M; Hayashi N
J Med Virol; 2007 May; 79(5):511-21. PubMed ID: 17385691
[TBL] [Abstract][Full Text] [Related]
19. Monocyte-derived dendritic cells in children with chronic hepatitis C: correlation with interferon and ribavirin therapy.
Khedr MA; E Behairy B; Hussein ME; Marei AM; Nage SA; Zakaria HM
Eur J Gastroenterol Hepatol; 2015 Oct; 27(10):1170-4. PubMed ID: 26148246
[TBL] [Abstract][Full Text] [Related]
20. Open, randomized, multicentre italian trial on PEG-IFN plus ribavirin versus PEG-IFN monotherapy for chronic hepatitis C in HIV-coinfected patients on HAART.
Cargnel A; Angeli E; Mainini A; Gubertini G; Giorgi R; Schiavini M; Duca P;
Antivir Ther; 2005; 10(2):309-17. PubMed ID: 15865225
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
